ONCURIOUS NV Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma - Seite 2
Ends
For further information please contact:
Oncurious / ThromboGenics Citigate Dewe Rogerson Wouter Piepers, David Dible/Sylvie Berrebi +32 16 75 13 10 / +32 478 33 56 32 Tel: +44 20 7638 9571 wouter.piepers@oncurious.com David.Dible@citigatedr.co.uk
Lesen Sie auch
About ONCURIOUS NV
ONCURIOUS NV is an oncology company focused on the development of innovative medicines for the treatment of pediatric cancers. Oncurious is a venture between ThromboGenics NV and VIB, a
leading life science research institute in Flanders, Belgium.
Oncurious is currently recruiting patients in a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare life-threatening brain tumor that mainly affects
children.
More information on Oncurious NV can be found at http://www.oncurious.com
About the NMTRC
The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) is a group of 25 universities and children's hospitals headquartered at the Helen Devos Children's Hospital,
Grand Rapids. MI, USA that offer a nationwide network of childhood cancer clinical trials. These trials are based on the research from a group of closely
collaborating investigators who are linked with laboratory programs developing novel therapies for high-risk neuroblastoma and medulloblastoma.
More information on NMTRC can be found at: http://nmtrc.org/
About BioInvent
BioInvent International AB (OMXS:BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are
BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has
an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December
2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic
institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer
Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials. More information is
available at http://www.bioinvent.com.